Loading
Organogenesis Holdings Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Mar 2026.
Organogenesis Holdings Inc.: what insiders have been doing
Every trade that managers of Organogenesis Holdings Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 35 filings signed by 15 insiders.
Both sides are active: 3 purchases worth €728k and 2 sales worth €1.3M, from 3 insiders and 1 insider respectively. Netting one side against the other leaves €610k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 3 senior executives. One trade stands out by size: a sale of €874k from Nussdorf Glenn H, disclosed on 18 December 2025.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 221 days ago, on 11 March 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
With 35 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. The full history, which starts in 2021, counts 16 purchases against 16 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 564.2 m USD and net income at 37.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
180
Thresholds
n/a
Buy Volume
€2M
16 ops. · all time
Sell Volume
€111M
16 ops. · all time
Who traded when
BuySaleGlenn H. Nussdorf1 buy2 sales
Gary S. Gillheeney2 sales
Michael Joseph Driscoll1 buy1 sale
Arthur S. Leibowitz1 buy
Lori Freedman1 buy
Since the insiders bought
- -6.8%Entry US$2.65 · Close at T+90 US$2.47
- -6.8%Entry US$2.65 · Close at T+90 US$2.47
- +9.0%Entry US$3.88 · Close at T+90 US$4.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Organogenesis Holdings Inc. Hold (neutral), based on 1 analysts. Average price target: US$2.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,710 of 24,148 companies
62.7
score / 100
Value69
Quality56
FCF yld-11%
Earn yld16%
EV/EBITDA3.8x
ROE-26%
Gross mgn76%
Net mgn6.6%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.79
Analyst consensus
1 analystsHold
US$2.00Target US$2.00(+12%)US$2.00
Income statement
RevenueUS$563M
Gross profitUS$425.5M76% margin
EBITDAUS$82.8M15% margin
Net incomeUS$37M-18.4% margin
Valuation
PER (forward)-5.8x
P/Book1.6x
Beta1.33
Balance sheet & cash
Market capUS$230.3M
Total debtUS$82.1M
Free Cash Flow-US$24.5M
Debt / Equity23%
Profitability & ownership
ROE-25.9%
ROA-4.1%
% insiders47.5%
% institutions51.8%
Last declaration on 24 April 2026
Declarations180 total
958 shares@ US$1.240.8% of flowClass A Common StockSEC:0002064832-26-000183:0
5,000 shares@ US$2.68145.7% of flowClass A Common StockSEC:0002064832-26-000129:0
Canonical exit: 7 Jun 2026 (T+90)
10,000 shares@ US$2.668813.8% of flowClass A Common StockSEC:0002064832-26-000127:0
Canonical exit: 7 Jun 2026 (T+90)
11,330 shares0Class A Common StockSEC:0002064832-26-000092:0
44,040 shares0Class A Common StockSEC:0002064832-26-000088:0
16,454 shares0Class A Common StockSEC:0002064832-26-000087:0
43,212 shares0Class A Common StockSEC:0002064832-26-000086:0
700 shares@ US$3.214.0% of flowClass A Common StockSEC:0002064832-26-000093:0
188,856 shares0Class A Common StockSEC:0002064832-26-000091:0
48,818 shares0Class A Common StockSEC:0002064832-26-000090:0
49,102 shares0Class A Common StockSEC:0002064832-26-000089:0
93,750 shares0Class A Common StockSEC:0002064832-26-000061:0
48,828 shares0Class A Common StockSEC:0002064832-26-000054:0
48,828 shares0Class A Common StockSEC:0002064832-26-000051:0
203,125 shares0Class A Common StockSEC:0002064832-26-000062:0
195,312 shares0Class A Common StockSEC:0002064832-26-000060:0
234,375 shares0Class A Common StockSEC:0002064832-26-000059:0
210,937 shares0Class A Common StockSEC:0002064832-26-000058:0
890,625 shares0Class A Common StockSEC:0002064832-26-000057:0
48,828 shares0Class A Common StockSEC:0002064832-26-000056:0
48,828 shares0Class A Common StockSEC:0002064832-26-000055:0
40,625 shares0Class A Common StockSEC:0002064832-26-000053:0
48,828 shares0Class A Common StockSEC:0002064832-26-000052:0
48,828 shares0Class A Common StockSEC:0002064832-26-000050:0
48,828 shares0Class A Common StockSEC:0002064832-26-000049:0
25 of 180 declarations
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a U.S.-based regenerative medicine company listed on the NASDAQ market in the United States. For French-, Belgian- and Swiss-based investors, the company can be viewed as a specialized healthcare platform focused on wound healing, tissue repair, and selected surgical and sports medicine applications. It was founded in 1985 as a spin-off from regenerative technology developed at the Massachusetts Institute of Technology (MIT), giving it a long operating history in biomaterials and biologics. Its corporate headquarters are in Canton, Massachusetts, with additional U.S. sites in Alabama, Florida, and California. The company also states that it manufactures its products in the United States, which is relevant for supply-chain control, quality positioning, and customer confidence in regulated healthcare markets.
Organogenesis’ business is organized around two main product areas. The first is Advanced Wound Care, which addresses chronic and complex wounds through a portfolio that includes well-known brands such as Apligraf, Dermagraft, PuraPly AM, NuShield, Affinity and other placental or collagen-based solutions. The second is Surgical & Sports Medicine, where the company markets products designed for operative, orthopedic, and sports medicine use, including NuShield, PuraForce, PuraPly SX and PuraPly MZ. This two-pronged model gives Organogenesis exposure to multiple points in the care continuum, from chronic wound management to surgical wound coverage and soft tissue support.
Read moreShow less
From a competitive standpoint, Organogenesis differentiates itself through a broad product portfolio, a long-standing clinical footprint, and a strong commercial presence in the U.S. Its history reflects both internal innovation and selective acquisitions: Apligraf was FDA-approved in the late 1990s, PuraPly was launched in 2015, and the 2017 acquisition of NuTech Medical expanded the company into surgical and sports medicine. The company also established a European office in Switzerland, which indicates a limited but meaningful international presence.
Recent developments have been mixed but important. In early 2025, the company reported a decline in first-quarter net revenue, yet third-quarter 2025 results showed record revenue and the fourth quarter of 2025 was also described as record-setting, driven primarily by strong growth in Advanced Wound Care. In March 2025, Organogenesis highlighted a significant CMS payment reform step for skin substitutes/cellular and tissue-based products, a potentially important catalyst for reimbursement visibility in the sector. At the same time, management disclosed in July 2025 that the second Phase 3 study of ReNu did not meet its primary endpoint, underscoring that pipeline execution remains a risk. Overall, ORGO is a niche healthcare equity on the NASDAQ with meaningful commercial scale in the U.S., attractive product depth, and high sensitivity to reimbursement policy, clinical adoption, and execution in a specialized medical market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
